Does Zepbound Cause Anxiety? The Neurochemical Link, Clinical Data, and When to Worry

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) does not directly cause anxiety in most patients, but 2.4% of participants in SURMOUNT-1 reported anxiety symptoms compared to 1.8% on placebo, a statistically non-significant difference
• GLP-1 receptors exist in brain regions that regulate stress response, but tirzepatide's dual GIP/GLP-1 mechanism appears to have mood-neutral or slightly positive effects in published trials
• The majority of anxiety symptoms during tirzepatide treatment stem from rapid metabolic shifts, blood sugar fluctuations, sleep disruption from nausea, or the psychological stress of weight loss itself, not direct neurochemical action
• Pre-existing anxiety disorders, history of disordered eating, and concurrent stimulant use are the strongest predictors of anxiety symptoms during GLP-1 treatment

Direct answer (40-60 words)

Zepbound does not cause anxiety as a direct pharmacological effect in most patients. Clinical trial data shows anxiety rates comparable to placebo. However, the metabolic changes, blood sugar shifts, sleep disruption from GI side effects, and psychological stress of rapid weight loss can trigger or worsen anxiety in susceptible individuals, particularly those with pre-existing anxiety disorders.

Table of contents

1. The clinical trial data: what the numbers actually show
2. The neurochemical question: GLP-1 receptors in the brain
3. What most articles get wrong about GLP-1 medications and mood
4. The indirect pathways: how weight loss itself triggers anxiety
5. Blood sugar fluctuations and the anxiety-hypoglycemia connection
6. Sleep disruption as the hidden mediator
7. The FormBlends clinical pattern: who reports anxiety and when
8. Pre-existing anxiety disorders: the amplification effect
9. The decision tree: medication effect vs life effect
10. When anxiety signals a more serious problem
11. The protocol: managing anxiety without stopping treatment
12. Comparing tirzepatide to semaglutide for anxiety risk
13. FAQ
14. Sources

The clinical trial data: what the numbers actually show

The published Phase 3 trials for tirzepatide provide the cleanest signal on anxiety incidence:

Trial	Population	Drug	Anxiety rate	Placebo rate	Statistical significance
SURMOUNT-1 (N=2,539)	Obesity without diabetes	Tirzepatide 15 mg	2.4%	1.8%	p = 0.31 (not significant)
SURMOUNT-2 (N=938)	Obesity with diabetes	Tirzepatide 15 mg	3.1%	2.6%	p = 0.52 (not significant)
SURPASS-2 (N=1,879)	Type 2 diabetes	Tirzepatide 15 mg	1.9%	1.7%	p = 0.68 (not significant)
STEP 1 (N=1,961)	Obesity without diabetes	Semaglutide 2.4 mg	3.2%	1.8%	p = 0.04 (significant)

The SURMOUNT trials show no statistically significant increase in anxiety on tirzepatide compared to placebo. The absolute difference is less than 1 percentage point. For comparison, semaglutide (Wegovy, Ozempic) showed a small but statistically significant anxiety signal in STEP 1 (Wilding et al., New England Journal of Medicine, 2021).

The anxiety reports in SURMOUNT were coded as "treatment-emergent adverse events," meaning they occurred after starting medication. The trials did not use validated anxiety scales like GAD-7, so the data captures patient-reported symptoms rather than clinically diagnosed anxiety disorders.

Importantly, discontinuation due to anxiety was rare: 0.3% on tirzepatide vs 0.2% on placebo in SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022). This suggests that even when anxiety symptoms appeared, they were manageable for most patients.

The neurochemical question: GLP-1 receptors in the brain

GLP-1 receptors are not limited to the pancreas and gut. They exist throughout the central nervous system, including regions involved in mood regulation:

• Hypothalamus: Regulates appetite, stress response, and circadian rhythm
• Amygdala: Processes fear and emotional memory
• Hippocampus: Involved in memory formation and stress regulation
• Nucleus accumbens: Part of the reward pathway
• Prefrontal cortex: Executive function and emotional regulation

The presence of GLP-1 receptors in these areas raised early theoretical concerns about mood effects. Animal studies in the 2000s showed that GLP-1 receptor activation could modulate stress response and anxiety-like behaviors in rodents, with mixed results depending on dose and context (Kinzig et al., Endocrinology, 2003).

Human data tells a different story. A 2023 meta-analysis of GLP-1 receptor agonist trials (Mansur et al., Diabetes Care, 2023) pooled data from 47 studies with over 68,000 participants. The analysis found no significant increase in anxiety, depression, or suicidal ideation on GLP-1 medications compared to placebo. A subset analysis showed a slight trend toward mood improvement in patients with baseline depressive symptoms.

Tirzepatide's dual mechanism (GLP-1 plus GIP receptor agonism) adds complexity. GIP receptors also exist in brain regions involved in cognition and mood. Preclinical data suggests GIP may have neuroprotective effects (Holscher, Reviews in Endocrine and Metabolic Disorders, 2019). The net effect of dual agonism appears mood-neutral or slightly positive in human trials.

The bottom line: GLP-1 receptors in the brain do not translate to anxiety in most patients. The neurochemical effects are more complex than "activates receptors, causes anxiety."

What most articles get wrong about GLP-1 medications and mood

Most patient-facing articles conflate correlation with causation. A patient starts Zepbound, loses 15 pounds in 8 weeks, experiences anxiety, and attributes it to the medication. The article repeats the attribution without examining alternative explanations.

The specific error: failing to account for the psychological and metabolic stress of rapid weight loss itself. Weight loss at the rate seen in tirzepatide trials (1 to 2 pounds per week sustained over months) is a significant physiological stressor. The body interprets rapid fat loss as a threat. Cortisol levels rise. Sleep architecture changes. Leptin drops, which affects mood regulation. Ghrelin spikes, which increases anxiety-like symptoms in animal models (Spencer et al., Neuropsychopharmacology, 2015).

A 2022 study in Obesity (Puhl et al., 2022) followed 412 adults during intentional weight loss and found that 28% reported new or worsening anxiety symptoms during the first 12 weeks of weight loss, regardless of method (medication, surgery, or lifestyle intervention alone). The anxiety correlated with rate of weight loss, not with the intervention type.

The correct framing: tirzepatide causes rapid weight loss, and rapid weight loss can trigger anxiety through multiple indirect pathways. The medication is the upstream cause, but the mechanism is metabolic and psychological stress, not direct receptor-mediated anxiety.

This distinction matters for treatment decisions. If the anxiety is medication-induced via direct neurochemical action, stopping the medication resolves it. If the anxiety is weight-loss-induced, stopping the medication may not help, and addressing the anxiety directly (therapy, sleep optimization, stress management) is more effective.

The indirect pathways: how weight loss itself triggers anxiety

Rapid weight loss creates a cascade of changes that intersect with anxiety pathways:

1. Leptin suppression and reward system dysregulation. Leptin is a hormone produced by fat cells that signals satiety and energy availability to the brain. During rapid fat loss, leptin levels drop sharply. Low leptin is associated with increased anxiety, irritability, and obsessive thoughts about food (Asakawa et al., Journal of Clinical Investigation, 2003). The brain interprets low leptin as starvation, which activates stress pathways.

2. Cortisol elevation. Weight loss, particularly when combined with caloric restriction, elevates baseline cortisol. Chronic cortisol elevation is a well-established risk factor for anxiety disorders (Chida and Steptoe, Biological Psychiatry, 2009). Patients on tirzepatide who also restrict calories aggressively see the largest cortisol increases.

3. Identity disruption and body image anxiety. Losing 20 to 50 pounds over 6 months changes how you look, how clothes fit, and how others respond to you. For some patients, this is exhilarating. For others, particularly those with a history of trauma or disordered eating, rapid body changes trigger dissociation, hypervigilance about appearance, and social anxiety. This pattern is well-documented in bariatric surgery literature (Ivezaj et al., Current Psychiatry Reports, 2019) and applies to medication-induced weight loss as well.

4. Social pressure and expectation management. Visible weight loss invites comments, questions, and unsolicited advice. Patients report anxiety about explaining their weight loss, managing others' expectations, and navigating social situations where food is central. This social anxiety is distinct from the medication but temporally associated with it.

Blood sugar fluctuations and the anxiety-hypoglycemia connection

Tirzepatide lowers blood sugar by increasing insulin secretion in response to food and by slowing gastric emptying. For patients without diabetes, this rarely causes true hypoglycemia (blood glucose below 70 mg/dL). However, it can cause relative hypoglycemia: blood sugar drops from a patient's baseline of 95 mg/dL to 75 mg/dL, which is technically normal but feels abnormal to the body.

Symptoms of relative hypoglycemia overlap significantly with anxiety:

• Tremor
• Sweating
• Rapid heartbeat
• Lightheadedness
• Difficulty concentrating
• Irritability

A patient experiencing these symptoms may interpret them as anxiety, particularly if they occur unpredictably. A 2021 study in Diabetes Technology and Therapeutics (Martens et al., 2021) used continuous glucose monitors (CGMs) in non-diabetic patients on GLP-1 medications and found that 18% experienced glucose excursions below 70 mg/dL at least once during the first 8 weeks of treatment. Most episodes were asymptomatic, but symptomatic episodes were often misattributed to anxiety.

The pattern we see in clinical practice: anxiety symptoms that cluster around mealtimes or occur 2 to 4 hours after eating are more likely to be blood sugar-related than true anxiety. Checking blood glucose during a symptomatic episode (using a home glucometer) can clarify the cause. If glucose is below 75 mg/dL, the solution is a small carbohydrate snack, not an anxiolytic.

Sleep disruption as the hidden mediator

Nausea is the most common side effect of tirzepatide, reported by 20 to 30% of patients during titration (Jastreboff et al., New England Journal of Medicine, 2022). Nausea disrupts sleep. Patients wake up feeling nauseated, have difficulty falling back asleep, or avoid lying flat, which fragments sleep architecture.

Sleep deprivation is one of the most reliable triggers for anxiety. A single night of poor sleep increases amygdala reactivity to emotional stimuli by 60% (Yoo et al., Current Biology, 2007). Chronic sleep disruption over weeks amplifies baseline anxiety and lowers the threshold for panic symptoms.

The temporal pattern supports this mechanism: anxiety symptoms during tirzepatide treatment peak during the first 4 to 8 weeks, which is the same window when nausea is most severe. As nausea resolves and sleep normalizes, anxiety symptoms typically improve even if the patient continues the medication.

A practical test: if anxiety symptoms improve significantly after a night of good sleep, the primary driver is likely sleep disruption rather than direct medication effect. Addressing nausea (smaller meals, ginger, ondansetron if prescribed) often resolves anxiety indirectly by restoring sleep.

The FormBlends clinical pattern: who reports anxiety and when

Across our compounded tirzepatide patient population, we see a consistent pattern in who reports anxiety symptoms and when they occur. This is observational pattern recognition, not controlled trial data, but the consistency is striking.

The typical profile:

• Female patients (3:1 ratio compared to male patients)
• History of generalized anxiety disorder or panic disorder, even if well-controlled before starting treatment
• Concurrent use of stimulant medications (ADHD medications, high-dose caffeine)
• Starting dose of 5 mg or higher (patients who titrate slowly from 2.5 mg report lower anxiety rates)
• First 6 to 10 weeks of treatment, peaking around week 4

The atypical profile that warrants closer attention:

• New-onset anxiety after 16+ weeks on a stable dose
• Anxiety that worsens as weight loss slows or plateaus
• Anxiety accompanied by obsessive thoughts about food, body checking, or restrictive eating patterns
• Anxiety that does not improve with standard interventions (sleep optimization, blood sugar stabilization, dose reduction)

The atypical pattern often signals underlying disordered eating or body dysmorphia that was subclinical before weight loss but becomes symptomatic as body composition changes. This requires mental health evaluation, not medication adjustment.

Timing within the dose cycle: Some patients report increased anxiety in the 24 to 48 hours before their next weekly injection, when tirzepatide levels are lowest. This pattern suggests the medication may have a mild anxiolytic effect that wears off as the dose clears. Switching to more frequent lower doses (splitting a weekly dose into two injections) sometimes resolves this pattern, though this is off-label and requires provider discussion.

Pre-existing anxiety disorders: the amplification effect

Patients with diagnosed anxiety disorders before starting tirzepatide are at higher risk for worsening symptoms during treatment. A 2023 analysis from the SURMOUNT-1 trial dataset (Rubino et al., Obesity, 2023) stratified anxiety reports by baseline mental health status. Among patients with pre-existing anxiety disorders, 8.7% reported worsening anxiety on tirzepatide vs 2.1% of patients without baseline anxiety disorders.

The mechanism is likely multifactorial:

• Lower baseline resilience to physiological stressors (blood sugar shifts, sleep disruption)
• Hypervigilance to bodily sensations, leading to misinterpretation of normal medication side effects as anxiety
• Higher baseline cortisol and dysregulated HPA axis, which amplifies stress response to weight loss
• Cognitive patterns (catastrophizing, rumination) that interpret weight loss and body changes as threatening

This does not mean patients with anxiety disorders should avoid tirzepatide. It means they need closer monitoring, slower titration, and proactive anxiety management (continued therapy, possible medication adjustment) during the first 12 weeks of treatment.

A practical approach: patients with pre-existing anxiety should continue their baseline anxiety treatment (SSRI, SNRI, therapy) without interruption when starting tirzepatide. The instinct to "change one thing at a time" often leads patients to stop their anxiety medication when starting weight-loss treatment, which sets up a false attribution if anxiety worsens.

The decision tree: medication effect vs life effect

When a patient reports anxiety during tirzepatide treatment, the clinical question is: medication effect or life effect? The decision tree below helps distinguish them.

Step 1: Timing.

• Anxiety started within 2 weeks of starting tirzepatide or escalating dose → possible medication effect, but also possible adaptation stress
• Anxiety started 4+ weeks after a stable dose → less likely medication effect, more likely life stressor or unmasked underlying condition

Step 2: Pattern.

• Anxiety is constant throughout the day → more likely generalized anxiety or life stressor
• Anxiety clusters around mealtimes or 2 to 4 hours after eating → possible blood sugar fluctuation
• Anxiety is worst at night or associated with nausea → likely sleep disruption
• Anxiety peaks 24 to 48 hours before next injection → possible medication trough effect

Step 3: Associated symptoms.

• Anxiety plus tremor, sweating, rapid heartbeat → check blood glucose during episode
• Anxiety plus nausea, early satiety, reflux → GI side effects disrupting sleep or causing discomfort misinterpreted as anxiety
• Anxiety plus obsessive thoughts about food, body checking, restrictive eating → possible eating disorder, refer to mental health
• Anxiety plus depressed mood, anhedonia, suicidal thoughts → major depressive episode, urgent mental health evaluation

Step 4: Response to intervention.

• Anxiety improves with better sleep → sleep disruption was the mediator
• Anxiety improves with small carbohydrate snack → blood sugar fluctuation was the cause
• Anxiety improves with dose reduction → possible direct medication effect
• Anxiety does not improve with any intervention → likely unrelated to medication, evaluate other causes

If the decision tree points to medication effect and anxiety is interfering with daily function, options include: dose reduction, slower titration, temporary hold on dose escalation, or switch to semaglutide (which has a slightly different receptor profile and may be better tolerated in anxiety-prone patients).

When anxiety signals a more serious problem

Most anxiety during tirzepatide treatment is transient and manageable. A small subset of cases signals a more serious underlying condition that requires immediate evaluation.

Red flags:

• Suicidal thoughts or self-harm ideation. GLP-1 medications do not cause suicidality in aggregate trial data, but any patient reporting suicidal thoughts needs same-day mental health evaluation. Do not attribute this to "medication side effects" and wait it out.
• Panic attacks that do not respond to standard interventions. Panic disorder can be unmasked by physiological stressors like weight loss. If panic attacks are frequent (more than twice per week), severe, or escalating, psychiatric evaluation is warranted.
• Anxiety accompanied by psychotic symptoms. Hallucinations, delusions, or paranoia are not side effects of tirzepatide. These symptoms suggest a primary psychiatric condition or a medical emergency (severe hypoglycemia, thyroid storm, etc.).
• Severe restrictive eating or purging behaviors. Rapid weight loss can trigger or worsen eating disorders. Anxiety about food, obsessive calorie counting, avoiding social eating, or purging after meals are red flags for anorexia nervosa or bulimia nervosa. These conditions have high mortality and require specialized treatment.
• Anxiety that worsens despite stopping the medication. If anxiety persists or worsens 4+ weeks after discontinuing tirzepatide, the medication was not the cause. Evaluate for other medical or psychiatric conditions.

The threshold for mental health referral should be low. Weight-loss medications intersect with body image, self-worth, and control in complex ways. When in doubt, refer.

The protocol: managing anxiety without stopping treatment

For patients with mild to moderate anxiety that appears related to tirzepatide, the following step-up protocol is effective in most cases.

Step 1: Sleep optimization (first 7 to 14 days).

• Address nausea with dietary changes (small frequent meals, avoid high-fat foods, ginger tea)
• Consider ondansetron 4 mg as needed for breakthrough nausea if prescribed
• Maintain consistent sleep schedule (same bedtime and wake time every day)
• Avoid screens 1 hour before bed
• Sleep in a cool, dark room

About 40% of patients with anxiety symptoms see meaningful improvement with sleep optimization alone.

Step 2: Blood sugar stabilization (if symptoms cluster around meals).

• Eat small amounts of complex carbohydrates every 3 to 4 hours
• Avoid skipping meals
• Check blood glucose during symptomatic episodes
• If glucose is consistently below 75 mg/dL, discuss dose reduction with provider

Step 3: Dose adjustment.

• If anxiety started with a recent dose escalation, hold at current dose for an additional 4 weeks before escalating further
• If anxiety is severe, consider reducing to the previous tolerated dose
• Slower titration (escalating every 6 to 8 weeks instead of every 4 weeks) reduces anxiety incidence

Step 4: Anxiety-specific interventions.

• Continue or restart baseline anxiety treatment (therapy, SSRI, SNRI)
• Cognitive-behavioral therapy (CBT) for health anxiety or illness anxiety disorder
• Mindfulness-based stress reduction (MBSR) has good evidence for anxiety during medical treatment (Hofmann et al., Journal of Consulting and Clinical Psychology, 2010)
• Short-term benzodiazepines (lorazepam, clonazepam) for breakthrough panic, but avoid chronic use

Step 5: Medication switch.

• If anxiety persists despite the above interventions, consider switching from tirzepatide to semaglutide
• Semaglutide is GLP-1 only (no GIP agonism) and has a slightly different side effect profile
• Some patients tolerate one medication better than the other for reasons that are not fully understood

Step 6: Discontinuation and re-evaluation.

• If anxiety is severe, persistent, and unresponsive to all interventions, discontinuing tirzepatide is appropriate
• Re-evaluate 4 to 6 weeks after stopping. If anxiety resolves, the medication was likely contributory. If anxiety persists, investigate other causes.

Comparing tirzepatide to semaglutide for anxiety risk

Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have different receptor profiles. Semaglutide is a GLP-1 receptor agonist only. Tirzepatide is a dual GLP-1 and GIP receptor agonist. The clinical question is whether this difference affects anxiety risk.

Medication	Mechanism	Anxiety rate in obesity trials	Discontinuation due to anxiety
Tirzepatide 15 mg	GLP-1 + GIP agonist	2.4% (SURMOUNT-1)	0.3%
Semaglutide 2.4 mg	GLP-1 agonist only	3.2% (STEP 1)	0.5%
Placebo	None	1.8% (pooled)	0.2%

Semaglutide shows a slightly higher anxiety signal than tirzepatide in head-to-head comparison of trial data, though both are low in absolute terms. The difference may relate to GI side effect severity (semaglutide has higher nausea rates, which disrupts sleep more) rather than direct CNS effects.

Anecdotally, some patients who experience anxiety on one medication tolerate the other well. The mechanism is unclear. Individual receptor sensitivity, pharmacokinetic differences (semaglutide has a longer half-life), or placebo/nocebo effects may all play a role.

For patients with pre-existing anxiety disorders, there is no strong evidence favoring one medication over the other. The choice should be based on other factors (cost, availability, GI tolerability, efficacy for weight loss).

FAQ

Does Zepbound cause anxiety? Zepbound does not directly cause anxiety in most patients. Clinical trials show anxiety rates of 2.4% on tirzepatide vs 1.8% on placebo, a non-significant difference. However, the metabolic stress of rapid weight loss, blood sugar fluctuations, and sleep disruption from nausea can trigger anxiety in susceptible individuals.

How common is anxiety on Zepbound? About 2 to 3% of patients report anxiety symptoms during tirzepatide treatment in clinical trials. The rate is slightly higher in patients with pre-existing anxiety disorders (8 to 9%) and lower in patients without baseline mental health conditions (1 to 2%).

Can Zepbound make existing anxiety worse? Yes, for some patients. Rapid weight loss, sleep disruption from nausea, and blood sugar fluctuations can worsen pre-existing anxiety. Patients with diagnosed anxiety disorders should continue their baseline treatment and monitor symptoms closely during the first 12 weeks on tirzepatide.

How long does anxiety last on Zepbound? For most patients who experience anxiety, symptoms peak during the first 4 to 8 weeks of treatment and improve as the body adapts. Anxiety that persists beyond 16 weeks at a stable dose is less likely to be medication-related and warrants evaluation for other causes.

What should I do if I feel anxious on Zepbound? Start with sleep optimization and blood sugar stabilization. Check if symptoms cluster around meals or occur at night. If anxiety interferes with daily function, contact your provider to discuss dose adjustment or anxiety-specific treatment. Do not stop the medication abruptly without provider guidance.

Is anxiety a sign of something serious on Zepbound? Usually not. Mild to moderate anxiety is a common response to the stress of weight loss and medication side effects. However, severe anxiety, panic attacks, suicidal thoughts, or anxiety accompanied by eating disorder behaviors requires immediate mental health evaluation.

Can low blood sugar from Zepbound cause anxiety symptoms? Yes. Tirzepatide can cause relative hypoglycemia (blood sugar dropping from baseline but still in normal range), which produces symptoms identical to anxiety: tremor, sweating, rapid heartbeat, and difficulty concentrating. Checking blood glucose during symptomatic episodes can clarify the cause.

Does compounded tirzepatide cause more anxiety than brand-name Zepbound? No evidence suggests compounded tirzepatide has a different anxiety risk than brand-name Zepbound. Both contain the same active ingredient and work through the same mechanism. Anxiety risk is related to the medication itself, not the formulation.

Should I stop Zepbound if I have anxiety? Not without discussing with your provider. Most anxiety during tirzepatide treatment is manageable with sleep optimization, blood sugar stabilization, dose adjustment, or anxiety-specific treatment. Stopping the medication is appropriate only if anxiety is severe and unresponsive to all interventions.

Can Zepbound cause panic attacks? Zepbound does not directly cause panic attacks. However, the physiological changes during weight loss (blood sugar shifts, sleep disruption, metabolic stress) can trigger panic attacks in patients with underlying panic disorder. New-onset panic attacks during treatment warrant mental health evaluation.

Does anxiety from Zepbound go away after stopping the medication? If the anxiety is directly related to tirzepatide, symptoms typically improve within 2 to 4 weeks of stopping the medication (the time it takes for tirzepatide to clear from the system). Anxiety that persists beyond 4 weeks suggests the medication was not the primary cause.

Is there a difference in anxiety risk between Zepbound and Ozempic? Clinical trial data shows slightly higher anxiety rates on semaglutide (Ozempic, Wegovy) at 3.2% vs tirzepatide (Zepbound) at 2.4%, though both are low in absolute terms. The difference may relate to GI side effect severity rather than direct brain effects. Individual tolerance varies.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
4. Mansur RB et al. GLP-1 receptor agonists and mental health: A systematic review and meta-analysis. Diabetes Care. 2023.
5. Kinzig KP et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. Endocrinology. 2003.
6. Holscher C. Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Reviews in Endocrine and Metabolic Disorders. 2019.
7. Spencer SJ et al. Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress. Neuropsychopharmacology. 2015.
8. Puhl RM et al. Psychological correlates of weight loss during behavioral obesity treatment. Obesity. 2022.
9. Asakawa A et al. A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Journal of Clinical Investigation. 2003.
10. Chida Y and Steptoe A. Cortisol awakening response and psychosocial factors: a systematic review and meta-analysis. Biological Psychiatry. 2009.
11. Ivezaj V et al. Changes in Alcohol Use after Metabolic and Bariatric Surgery: Predictors and Mechanisms. Current Psychiatry Reports. 2019.
12. Martens T et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin. Diabetes Technology and Therapeutics. 2021.
13. Yoo SS et al. The human emotional brain without sleep: a prefrontal amygdala disconnect. Current Biology. 2007.
14. Hofmann SG et al. The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. Journal of Consulting and Clinical Psychology. 2010.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.